Endometrial cancer is the most commonly diagnosed gynecological cancer. Credit: Darryl Leja, NHGRI.

Innovent Biologics has reported positive results from two clinical trials of IBI305 after meeting the pre-defined primary endpoints of both studies.

China-based Innovent’s IBI305 is a biosimilar of bevacizumab, which is a recombinant humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody developed for use as injection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The CIBI305A301 and CIBI305A201 trials evaluated IBI305 in comparison with bevacizumab to treat advanced non-squamous non-small cell lung cancer (NSCLC), a type of epithelial lung cancer.

CIBI305A301 is a Phase III trial that evaluated the efficacy and safety of IBI305 and bevacizumab in patients with advanced non-squamous NSCLC.

“The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden.”

The randomised, double-blinded, parallel, positive-controlled trial enrolled 450 patients and aims to compare the clinical activity and safety of IBI305 and bevacizumab in combination with paclitaxel / carboplatin.

Its primary endpoint includes objective response rate (ORR).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CIBI305A201 trial intends to investigate the pharmacokinetic profile, safety, tolerability, and immunogenicity of IBI305 in comparison with bevacizumab.

A total of 100 subjects were included in the randomised, double-blinded, parallel, positive-controlled single-dose trial.

Primary endpoint of the trial is to compare the pharmacokinetic (PK) profile of IBI305 and bevacizumab.

Innovent Biologics founder, CEO and chairman Michael Yu said: “The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden for millions of families.

“Anti-angiogenic drugs are effective anti-tumour treatments, but as of yet there are no approved bevacizumab biosimilars in China.

“The clinical studies of IBI305, a potential biosimilar of bevacizumab, are encouraging.”